These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

970 related articles for article (PubMed ID: 32540959)

  • 1. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options.
    Löscher W; Potschka H; Sisodiya SM; Vezzani A
    Pharmacol Rev; 2020 Jul; 72(3):606-638. PubMed ID: 32540959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural product-derived therapies for treating drug-resistant epilepsies: From ethnopharmacology to evidence-based medicine.
    Challal S; Skiba A; Langlois M; Esguerra CV; Wolfender JL; Crawford AD; Skalicka-Woźniak K
    J Ethnopharmacol; 2023 Dec; 317():116740. PubMed ID: 37315641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug development for refractory epilepsy: The past 25 years and beyond.
    Golyala A; Kwan P
    Seizure; 2017 Jan; 44():147-156. PubMed ID: 28017578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of action of currently used antiseizure drugs.
    Sills GJ; Rogawski MA
    Neuropharmacology; 2020 May; 168():107966. PubMed ID: 32120063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Models in research of pharmacoresistant epilepsy: present and future in development of antiepileptic drugs.
    Kovács R; Heinemann U
    Curr Med Chem; 2014; 21(6):689-703. PubMed ID: 24251565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Animal Models of Drug-Resistant Epilepsy as Tools for Deciphering the Cellular and Molecular Mechanisms of Pharmacoresistance and Discovering More Effective Treatments.
    Löscher W; White HS
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.
    Löscher W
    Neurochem Res; 2017 Jul; 42(7):1873-1888. PubMed ID: 28290134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do we choose the appropriate animal model for antiseizure therapy development?
    Barker-Haliski M
    Expert Opin Drug Discov; 2019 Oct; 14(10):947-951. PubMed ID: 31248287
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms.
    Schmidt D; Löscher W
    Epilepsia; 2005 Jun; 46(6):858-77. PubMed ID: 15946327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies.
    Christian CA; Reddy DS; Maguire J; Forcelli PA
    Pharmacol Rev; 2020 Oct; 72(4):767-800. PubMed ID: 32817274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Refractory epilepsy].
    Gueguen B
    Presse Med; 1998 Dec; 27(39):2036-42. PubMed ID: 9893695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical re-evaluation of previous preclinical strategies for the discovery and the development of new antiepileptic drugs.
    Löscher W; Leppik IE
    Epilepsy Res; 2002 Jun; 50(1-2):17-20. PubMed ID: 12151113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New avenues for anti-epileptic drug discovery and development.
    Löscher W; Klitgaard H; Twyman RE; Schmidt D
    Nat Rev Drug Discov; 2013 Oct; 12(10):757-76. PubMed ID: 24052047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New horizons in the development of antiepileptic drugs: the search for new targets.
    Löscher W; Schmidt D
    Epilepsy Res; 2004; 60(2-3):77-159. PubMed ID: 15540387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.
    Löscher W; Klein P
    CNS Drugs; 2021 Sep; 35(9):935-963. PubMed ID: 34145528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening.
    Griffin A; Hamling KR; Hong S; Anvar M; Lee LP; Baraban SC
    Front Pharmacol; 2018; 9():573. PubMed ID: 29915537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches.
    Leandro K; Bicker J; Alves G; Falcão A; Fortuna A
    Pharmacol Res; 2019 Jun; 144():357-376. PubMed ID: 31051235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologically targeting transient receptor potential channels for seizures and epilepsy: Emerging preclinical evidence of druggability.
    Jiang J; Yu Y
    Pharmacol Ther; 2023 Apr; 244():108384. PubMed ID: 36933703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?
    Löscher W
    Neurochem Res; 2017 Jul; 42(7):1926-1938. PubMed ID: 27502939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies for the identification of drugs to prevent the development or progression of epilepsy.
    Schmidt D; Rogawski MA
    Epilepsy Res; 2002 Jun; 50(1-2):71-8. PubMed ID: 12151119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.